IL298399A - Treatment of facial wrinkles with the botulinum toxin in high dose and low volume - Google Patents

Treatment of facial wrinkles with the botulinum toxin in high dose and low volume

Info

Publication number
IL298399A
IL298399A IL298399A IL29839922A IL298399A IL 298399 A IL298399 A IL 298399A IL 298399 A IL298399 A IL 298399A IL 29839922 A IL29839922 A IL 29839922A IL 298399 A IL298399 A IL 298399A
Authority
IL
Israel
Prior art keywords
botulinum toxin
lines
treatment
dose
days
Prior art date
Application number
IL298399A
Other languages
English (en)
Hebrew (he)
Inventor
Roll Susanna
Sladek Meik
Geister Thorin
Pulte Irena
Weissenberger Petra
Klein Gudrun
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Roll Susanna
Sladek Meik
Geister Thorin
Pulte Irena
Weissenberger Petra
Klein Gudrun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71016459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL298399(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa, Roll Susanna, Sladek Meik, Geister Thorin, Pulte Irena, Weissenberger Petra, Klein Gudrun filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of IL298399A publication Critical patent/IL298399A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL298399A 2020-06-05 2021-06-04 Treatment of facial wrinkles with the botulinum toxin in high dose and low volume IL298399A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20178574 2020-06-05
PCT/EP2021/064986 WO2021245223A1 (en) 2020-06-05 2021-06-04 High dose and low volume botulinum toxin treatment of facial wrinkles

Publications (1)

Publication Number Publication Date
IL298399A true IL298399A (en) 2023-01-01

Family

ID=71016459

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298399A IL298399A (en) 2020-06-05 2021-06-04 Treatment of facial wrinkles with the botulinum toxin in high dose and low volume

Country Status (13)

Country Link
US (2) US12599550B2 (enExample)
EP (2) EP4161562B1 (enExample)
JP (2) JP2023529095A (enExample)
KR (1) KR20230020961A (enExample)
CN (1) CN115666629A (enExample)
AU (1) AU2021286196A1 (enExample)
BR (1) BR112022023413A2 (enExample)
CA (1) CA3177835A1 (enExample)
ES (1) ES3013130T3 (enExample)
IL (1) IL298399A (enExample)
MX (1) MX2022014564A (enExample)
TW (1) TW202214211A (enExample)
WO (1) WO2021245223A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298399A (en) 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume
TWI852454B (zh) * 2022-04-01 2024-08-11 大陸商重慶譽顏製藥有限公司 一種肉毒毒素蛋白組合物、製備方法及其應用
KR20250113431A (ko) * 2022-11-28 2025-07-25 메르츠 파마 게엠베하 운트 코. 카가아 목을 재생하기 위한 고 농도 보툴리눔 독소 치료
WO2025231403A1 (en) * 2024-05-03 2025-11-06 Revivity Pharma Corporation Methods of administering and manufacturing toxic compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
EP1786459B1 (en) 2004-07-26 2014-02-12 Merz Pharma GmbH & Co. KGaA Therapeutic composition whit a botulinum neurotoxin
EP2072039A1 (en) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
MY155049A (en) 2008-03-14 2015-08-28 Allergan Inc Immuno-based botolinum toxin serotype a activity assay
LT2761065T (lt) * 2011-09-29 2018-01-10 Cellsnap, Llc Kompozicijos ir būdai toksigeniškumo testavimui
US11976110B2 (en) 2013-06-28 2024-05-07 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
RU2020121540A (ru) 2017-12-04 2022-01-10 Реванс Терапьютикс, Инк. Инъецируемые составы ботулинического токсина и способы их применения с высокими показателями ответа и длительной продолжительностью эффекта
IL298399A (en) 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume

Also Published As

Publication number Publication date
EP4161562A1 (en) 2023-04-12
EP4467202A2 (en) 2024-11-27
KR20230020961A (ko) 2023-02-13
US20260144733A1 (en) 2026-05-28
JP2023529095A (ja) 2023-07-07
MX2022014564A (es) 2022-12-15
EP4161562B1 (en) 2024-11-20
WO2021245223A1 (en) 2021-12-09
CN115666629A (zh) 2023-01-31
EP4467202A3 (en) 2025-02-19
TW202214211A (zh) 2022-04-16
CA3177835A1 (en) 2021-12-09
AU2021286196A1 (en) 2022-12-01
ES3013130T3 (en) 2025-04-11
JP2026077675A (ja) 2026-05-13
US12599550B2 (en) 2026-04-14
US20230329996A1 (en) 2023-10-19
BR112022023413A2 (pt) 2022-12-20

Similar Documents

Publication Publication Date Title
US12599550B2 (en) High dose and low volume botulinum toxin treatment of facial wrinkles
US12409211B2 (en) Non-protein Clostridial toxin compositions
US8241640B2 (en) Pharmaceutical botulinum toxin compositions
ES2880281T3 (es) Nanoemulsiones de botulinum
JP7579046B2 (ja) ボツリヌス毒素を含む組成物
US8658391B2 (en) Assessment of the effects of topical administration of chemodenervating pharmaceuticals
US20030224020A1 (en) Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
JP2013006861A (ja) 改良されたボツリヌス毒素組成物
WO2020056371A1 (en) Clostridial toxin-hyaluronic acid compositions
CA2667536A1 (en) Highly purified type a botulinum toxin preparation from infant botulism pathogen
Dutton et al. Myobloc® for the treatment of benign essential blepharospasm in patients refractory to Botox®
Boone et al. Botulinum toxin in aesthetic medicine
RU2835617C1 (ru) Лечение морщин на лице высокой дозой и малым объемом ботулинического токсина
Waugh et al. Nonclinical and clinical experiences with CPP-based self-assembling peptide systems in topical drug development
US20240207303A1 (en) mNA-based Delivery of Botulinum Toxin
HK40085901A (en) High dose and low volume botulinum toxin treatment of facial wrinkles
US20240226251A1 (en) Combination therapy using clostridial toxin derivative and at least one chemical depolarizing agent
US20240000905A1 (en) Polymeric nanoparticle compositions for encapsulation and sustained release of neuromodulators